Skip to main content

Gout

#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj
Dr. John Cush @RheumNow( View Tweet )
Jun 18, 2022
Gout Undertreatment Persists Despite updated gout management guidelines from EULAR and BSR, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.https://t.co/qW7ZaXbnx3 https://t.co/ZBKIjuQp10
Dr. John Cush @RheumNow( View Tweet )
Jun 10, 2022
gout.toe_.MTP_.jpg

Gout Undertreatment Persists

Jun 08, 2022

Despite updated gout management guidelines from European (EULAR) and British (BSR) societies, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.



A cohort analysis using UK gout patients (n = 

Read Article
Topical therapies take centre stage Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. #EULAR2022 https://t.co/V9plk1vAEd https://t.co/fyNWWtconi
Dr. John Cush @RheumNow( View Tweet )
Jun 06, 2022
ice cubes

Topical therapies take centre stage

Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. 

Read Article
gout.MTP1_.jpg

Real World Data on Urate Lowering Therapy

Jun 04, 2022

Urate lowering therapy (ULT) is the backbone therapy for long-term gout treatment and maintenance, but real-world gout management is often imperfect and suboptimal. 

Read Article
#EULAR2022 POS0285 130K UK patients had incident gout bw 2004-2020 ⭐️Only 29% started on ULT w/in 12 mos ⭐️Target urate level only 14% in 2004, only to 17% in 2020 Updated EULAR guidelines in 2016: No statistical difference in ULT Rx or target attainment @Rheumnow
Jun 04, 2022
#EULAR2022 POS0282 Febuxostat vs allopurinol: CV risk population study ⭐️16% reduction in all-cause mortality among febuxostat users, mostly non-CV death reduction ⭐️CV safety non-inferior to allopurinol @Rheumnow https://t.co/1oDSioQWPT
Jun 04, 2022
#EULAR2022 POS0283: Do Rheums have Gout Stigma? ⭐️Stereotypes about pt related factors ⭐️Rheumatologists feel diet, exercise, wt loss more important in gout than RA, pharmacologic therapies less important than RA @Rheumnow
Jun 04, 2022
#EULAR2022 POS0280 Gout is associated with higher mortality in Women ⭐️Higher all cause and CV mortality RR 1.28 risk of mortality in pts without CHD, with gout compared to controls (No CHD or gout) @Rheumnow https://t.co/6o1EKSp2F8
Jun 04, 2022
So what diet to follow with autoimmunity in mind? So many, all with different instructions. Let’s concentrate on where they agree: yes to fruits & vegetables no to emulsifiers & processed foods #EULAR2022 @RheumNow https://t.co/I9abweQOyZ
Jun 03, 2022
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow
Jun 03, 2022
#EULAR2022 POS0278: Proof of concept US study: 💎CPP crystals do NOT generate posterior shadowing 💎MSU and hydroxyapatite did have shadowing, proportional to concentration of crystals @Rheumnow @MymaAlbaydaMD @USSONAR_Rh
Jun 03, 2022
acr_session2.jpeg

EULAR 2022 – Day 2 Report

Jun 02, 2022

A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.

Read Article
Dr Puja Khanna. Transdermal sodium bicarbonate for gout flare. WHAT!? It works as well! Double-blind RCT. All got colchicine also. Response rate 95% vs 79%. Resolution in 24 vs 72 hrs. Rescue meds 6% vs 20%. No adverse events! @RheumNow #EULAR2022 OP0170 https://t.co/INd4tMFVlV https://t.co/EyVjFLF72z
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2022
Farshad et al. 17% of admissions on long-term allopurinol had it held. Reasons - acute gout flare, renal impairment, gastrointestinal issues, cytopenia, drug interactions, NPO status, and always discontinued the medication. @RheumNow #EULAR2022 OP0169 https://t.co/ADOomiOrRi https://t.co/nxAAOMWsJB
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2022
Botson et al. 152 patient RCT. MTX combo with pegloticase (to decrease antidrug abs). 6-month response (sUA<6 mg/dL) 71% vs 39%. Infusion reactions 3% vs 31%. @RheumNow #EULAR2022 OP0171 https://t.co/N29kYT3xkR https://t.co/Z4dUMD4Tt3
Richard Conway @RichardPAConway( View Tweet )
Jun 01, 2022
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on https://t.co/V10S4oVFsv. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?https://t.co/iaMQZtzdLm https://t.co/Zu9VwKoCAc
Dr. John Cush @RheumNow( View Tweet )
May 28, 2022
RheumNow Podcast square

Recommendations – Good & Bad (5.27.2022)

May 27, 2022

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?




  1. May 2022 EMA meeting the CHMP recommended new indications for

Read Article
To TDM or Not in Rheumatology? Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation...https://t.co/u86Vd8bFGr#MedEdTwitter https://t.co/IpKqPoWM9R
Dr. John Cush @RheumNow( View Tweet )
May 26, 2022
cardiac2.jpg (keep)

Cardiovascular Risk in Calcium Pyrophosphate Deposition Disease

May 26, 2022

The cardiovascular (CV) risks of inflammation and gout are well known, but until recently hasn't been tied to calcium pyrophosphate deposition (CPPD) disease. A recent EHR study shows that acute CPPD crystal arthritis was significantly associated with elevated risks for non-fatal CV events.

Read Article
1049 non-diabetic hospitalized gout pts (2014 -2020); saw an inverse relationship betw CKD & NAFLD, & increaseing negative associations w/ NAFLD severity (mild OR 0.392; Mod: 0.379; Severe 0.148). NAFLD negatively assoc w/ CKD risk in gout https://t.co/5fuIiO1LwM https://t.co/Jp8CjWkn5m
Dr. John Cush @RheumNow( View Tweet )
May 26, 2022
dementia,brain

Is Gout Protective Against Dementia?

MedPage Today
May 25, 2022

People with gout appeared less likely to develop dementia than age- and sex-matched peers, a database study from Korea found.



The analysis of more than 5,000 gout patients and 25,000 controls in Korea's national healthcare system yielded adjusted hazard ratios of 0.79 for overall new-

Read Article
Study of 100 pts w/ gouty arthritis, 51% had hypertension, nearly half insufficiently controlled. Undiagnosed HTN was seen in 18%. Gouty pts w/ HTN frequently (92%) had serum uric acid levels above the target https://t.co/jc0UGyrK2B https://t.co/kDD2KfQd3K
Dr. John Cush @RheumNow( View Tweet )
May 25, 2022
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush @RheumNow( View Tweet )
May 25, 2022
×